The Pharmacy Times® Hematology Resource Center is a comprehensive resource for clinical news and expert insights on the treatment of blood disorders, including blood and bone marrow cancers, leukemia, and myeloma.
July 31st 2025
Sanofi's SAR446523 receives orphan drug designation for relapsed refractory multiple myeloma, enhancing treatment options and patient outcomes.
Mortality and Causes of Death in Patients With Polycythemia Vera
December 6th 2020Pharmacy Times® interviewed Brady Stein, MD, MHSc, of the Feinberg School of Medicine at Northwestern University, on what polycythemia vera (PV) is and why it was important to understand mortality and causes of death among patients with PV.
Watch
The Causes of Sickle Cell Disease and Beta-thalassemias
December 5th 2020Pharmacy Times® interviewed Christopher Moxham of Fulcrum Therapeutics, on what sickle cell disease and beta-thalassemias are caused by, and how hemoglobin gamma can prevent or reduce disease-related pathophysiology in these disorders.
Watch
New Data on Gilteritinib in AML Presented at 2020 American Society of Hematology Annual Meeting
December 4th 2020Five oral presentations will include data on the use of gilteritinib, either as monotherapy or in combination, across the spectrum of patients with acute myeloid leukemia with a positive FLT3 mutation.
Read More
More Than 4 Million Potential Years of Life Lost to Cancer Deaths in 2017
November 25th 2020Although cancer deaths with the highest death rates per capita accounted for the greatest number of years lost, the study authors said cancers that typically occur in younger populations had a disproportionate share of the burden.
Read More
X-ray Study Explores Potential of Hepatitis C Drugs to Treat COVID-19
November 19th 2020The study was done in an effort to help quickly develop pharmaceutical treatments for COVID-19 by repurposing existing drugs known to effectively treat other viral diseases, according to the study authors.
Read More
Study: Patients With COVID-19 Should Continue Treatment With ACE Inhibitors, ARBs
November 19th 2020Results of a recent study confirmed that patients already taking angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) should not discontinue taking them due to COVID-19 infection.
Read More
COVID-19 and Atrial Arrhythmias May Increase Risk of Major Adverse Cardiac Events, Death
November 18th 2020For patients with COVID-19, the combination of the disease and preexisting atrial arrhythmias may create a pathologic synergy that significantly increases the risk for major adverse cardiac events and death.
Read More
Study: Bursts of Exercise Can Lead to Significant Improvements in Indicators of Metabolic Health
November 18th 2020The research team described how approximately 12 minutes of acute cardiopulmonary exercise affected more than 80% of circulating metabolites, including pathways linked to a wide range of favorable health outcomes, thus identifying potential mechanisms that could contribute to a better understanding of the cardiometabolic benefits of exercise.
Read More
FDA Review of BLA for Liso-Cel in Relapsed/Refractory Large B-Cell Lymphoma Delayed by COVID-19
November 18th 2020A review of the biologics license application for lisocabtagene maraleucel in the treatment of relapsed/refractory large B-cell lymphoma following at least 2 previous therapies has been delayed.
Read More
Study: Children Exposed to Tobacco Smoke at Home Have Worse Heart Function as Adults
November 17th 2020The researchers examined the health records of more than 1100 adults, who had an average age of 45 years, were 52% female, and who are participants in the ongoing Childhood Determinants of Adult Health study.
Read More
Study: Plasma Treatment Quickly Kill Coronavirus on Surfaces
November 12th 2020In a study published in Physics of Fluids, modeling conducted in June 2020 showed strains of COVID-19 on surfaces—such as metal, leather, and plastic—were killed in as little as 30 seconds of treatment with argon-fed, cold atmospheric plasma.
Read More
Study Supports Use of Radiation Before CAR-T Cell Therapy for Multiple Myeloma
November 5th 2020The study found patients who received radiation 34 days or fewer before their infusion with CART-B cell maturation antigen (BCMA) cells did not have worse rates of severe cytokine release syndrome or neurotoxicity, which are 2 common adverse effects of the cellular therapy.
Read More